Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

BACKGROUND: This phase 1 first-in-human study aimed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and safety of E6201, and to establish recommended dosing in patients with advanced solid tumours, expanded to advanced melanoma. METHODS: Part A (dose escalation): sequential...

Descripción completa

Detalles Bibliográficos
Autores principales: Tibes, Raoul, Borad, Mitesh J., Dutcus, Corina E., Reyderman, Larisa, Feit, Kevie, Eisen, Andrew, Verbel, David A., Von Hoff, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008465/
https://www.ncbi.nlm.nih.gov/pubmed/29867224
http://dx.doi.org/10.1038/s41416-018-0099-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008465/
https://www.ncbi.nlm.nih.gov/pubmed/29867224
http://dx.doi.org/10.1038/s41416-018-0099-5

Ejemplares similares